Setmelanotide
FDA expands setmelanotide approval for rare forms of obesity to children aged 2 to 5 years
The FDA approved an expanded indication for setmelanotide to include children aged 2 to 5 years with several genetic forms of obesity, Rhythm Pharmaceuticals announced.
Top in endocrinology: Setmelanotide reduces BMI; dangers of endocrine-disrupting chemicals
Results of a phase 2 trial showed that 89% of children and adults with hypothalamic obesity had a 5% or greater reduction in BMI after receiving setmelanotide over 16 weeks.
Setmelanotide lowers BMI by 5% or more for most people with hypothalamic obesity
Setmelanotide reduced BMI by at least 5% at 16 weeks among 89% of children and adults with hypothalamic obesity, according to findings from a phase 2 trial published in The Lancet Diabetes & Endocrinology.
People with Bardet-Biedl syndrome lower metabolic syndrome score with setmelanotide
DALLAS — Setmelanotide may lower the risk for metabolic syndrome for people with a rare monogenic form of obesity, according to data presented at ObesityWeek.
Setmelanotide may cut metabolic syndrome risk in rare monogenic forms of obesity
DALLAS — People with rare monogenic forms of obesity may reduce their risk for metabolic syndrome with setmelanotide therapy, according to research presented at ObesityWeek.
Setmelanotide reduces hyperphagia, improves quality of life in Bardet-Biedl syndrome
Treatment with the melanocortin-4 receptor agonist setmelanotide reduced hyperphagia and led to improvements in emotional well-being among children and adults with Bardet-Biedl syndrome, according to study findings.
Setmelanotide significantly reduces body weight for people with Bardet-Biedl syndrome
Setmelanotide led to significant reductions in weight among people with obesity and the genetic disorder Bardet-Biedl syndrome, but not Alström syndrome, according to findings published in The Lancet Diabetes & Endocrinology.